Phase 3 multicenter randomized double-blind group sequential placebo-controlled study to assess efficacy and safety of rimegepant for the treatment of migraine (with or without aura) in children and adolescents = 6 to
Brief description of study
The main purpose of this study is to learn how well the study drug works and how safe the study drug is in children and young people compared with placebo. A placebo is an inactive material that looks like the study drug but does not contain any active study drug. Researchers use a placebo to see if the study drug works better or is safer than taking nothing.
Clinical Study Identifier: s21-00736
ClinicalTrials.gov Identifier: NCT04649242
Principal Investigator:
Vijaya L Atluru.
Other Investigator:
Chaula Kharode.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.